Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor: Clinical activity and favorable safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Meeting Abstract
| Authors: | Morschhauser, F.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Johnson, P.; Le Gouill, S.; Dickinson, M.; Fruchart, C.; Lamy, T.; Chaidos, A.; Jurczak, W.; Opat, S.; Radford, J.; Zinzani, P. L.; Assouline, S.; Cartron, G.; Clawson, A.; Picazio, N.; Ribich, S.; Blakemore, S.; Larus, J.; Miao, H.; Woodruff, M.; Ho, P.; Ribrag, V. |
| Abstract Title: | Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor: Clinical activity and favorable safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma |
| Meeting Title: | 5th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 17 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Sep 13-16 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-09-01 |
| Start Page: | S380 |
| End Page: | S381 |
| Language: | English |
| ACCESSION: | 124936209 |
| DOI: | 10.1016/j.clml.2017.07.227 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: NHL-255 -- Accession Number: 124936209 -- Entry Date: In Process -- Revision Date: 20170904 -- Publication Type: Article -- Supplement Title: Sep2017 Supplement 2 -- Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101525386. -- Source: cin20 |
